Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...